BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a RegistrantItem 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.
U.S. Dollar Notes Offering
On March 1, 2018, Becton, Dickinson and Company (the “Company” or “BD”) issued $1,000,000,000 aggregate principal amount of Floating Rate Notes due December 29, 2020 (the “Notes”) in an underwritten public offering to the indenture, dated March 1, 1997, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Indenture”).
The Company may, at its option, redeem the Notes, in whole or in part, from time to time, on the first business day after the date that is one year following the date of issuance of the Notes or at any time or from time to time thereafter at a price equal to 50% of the aggregate principal amount of Notes being redeemed, plus accrued and unpaid interest to the redemption date.
Upon the occurrence of a Change of Control Triggering Event (as defined in the Notes), each holder of outstanding Notes will have the right to require the Company to purchase all or a portion of that holder’s Notes (in integral multiples of $1,000) at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase, subject to the rights of holders of such Notes on the relevant record date to receive interest due on the relevant interest payment date, unless the Company has earlier exercised its right to redeem the Notes as described above.
Each of the following constitutes an event of default under the Indenture with respect to the Notes: (1) failure to pay any installment of interest on the Notes when due and payable, continued for 30 days; (2) failure to pay the principal when due of the Notes, whether at stated maturity or otherwise; (3) failure to observe or perform any other covenants, conditions or agreements of the Company with respect to the Notes for 60 days after the Company receives notice of such failure; or (4) certain events of bankruptcy, insolvency or reorganization. If an event of default occurs, the principal amount of the Notes may be accelerated to the Indenture.
The Indenture includes requirements that must be met if the Company consolidates or merges with, or sells all or substantially all of the Company’s assets to, another entity. The Indenture also contains certain restrictive covenants, including a limitation on liens and a restriction on sale and leasebacks.
The foregoing summary is qualified in its entirety by reference to the text of the Indenture, a copy of which is incorporated by reference from Exhibit 4(a) to the Company’s Current Report on Form 8-K filed on July 31, 1997, and the Notes, a form of which is attached as Exhibit 4.1 to this Current Report on Form 8-K.
Item 8.01 Other Events.
U.S. Dollar Notes Offering
On February 27, 2018, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”) in connection with the offer and sale by the Company to the Underwriters of the Notes described in Item 2.03 above.
The Company expects to use the net proceeds from the offering of the Notes, together with the net proceeds of the Company’s previously announced offering of additional 0.368% Notes due 2019 that was consummated on February 22, 2018, to repay $1.366 billion principal amount outstanding under its three-year term loan facility incurred in connection with financing the acquisition of C. R. Bard, Inc.and its revolving credit facility and to pay accrued interest, related premiums, fees and expenses in connection therewith.
The foregoing description of the Underwriting Agreement does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| 1.1 | Underwriting Agreement, dated February 27, 2018, by and among Becton, Dickinson and Company, Barclays Capital Inc. and Wells Fargo Securities, LLC. |
|
4.1 |
Form of Floating Rate Note due December 29, 2020. |
| 5.1 | Opinion of Gary DeFazio, Senior Vice President, Corporate Secretary and Associate General Counsel of Becton, Dickinson and Company. |
| 5.2 | Opinion of Skadden, Arps, Slate, Meagher & Flom LLP. |
| 12.1 | Computation of Ratio of Earnings to Fixed Charges. |
| 23.1 | Consent of Gary DeFazio, Senior Vice President, Corporate Secretary and Associate General Counsel of Becton, Dickinson and Company (included as part of Exhibit 5.1). |
| 23.2 | Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included as part of Exhibit 5.2). |
INDEX TO EXHIBITS
| Exhibit Number | Description | |
|---|---|---|
| 1.1 | Underwriting Agreement, dated February 27, 2018, by and among Becton, Dickinson and Company, Barclays Capital Inc. and Wells Fargo Securities, LLC. | |
| 4.1 |
Form of Floating Rate Note due December 29, 2020. |
|
| 5.1 | Opinion of Gary DeFazio, Senior Vice President, Corporate Secretary and Associate General Counsel of Becton, Dickinson and Company. | |
| 5.2 | Opinion of Skadden, Arps, Slate, Meagher & Flom LLP. | |
| 12.1 | Computation of Ratio of Earnings to Fixed Charges. | |
| 23.1 | Consent of Gary DeFazio, Senior Vice President, Corporate Secretary and Associate General Counsel of Becton, Dickinson and Company (included as part of Exhibit 5.1). | |
| 23.2 | Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included as part of Exhibit 5.2). | |
BECTON DICKINSON & CO ExhibitEX-1.1 2 s002096x4_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION VERSION Becton,…To view the full exhibit click here
About BECTON, DICKINSON AND COMPANY (NYSE:BDX)
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.